×
Agenda will be updated shortly. Stay tuned
×
- Please click the timestamp to watch topic you are interested in.
- 00:00 Introduction
- “An apple a day to keep diabetes at bay” – Going beyond glucose with SGLT2i - 5:56 Old strategies – and their benefits - 10:45 New medications – better chances - 20:09 New medications include a paradigm shift - 25:42 Take home message
- “An apple a day to keep diabetes at bay” – How do they work - 28:35 The mechanism for kidney protection
- “Making the evolution of diabetes management a revolution” – Panel discussion - 47:55 Patient case introduction - 50:24 What should we have done with this patient? - 53:33 Risk factor management or Organ protection management? - 57:50 How to overcome inertia that SGLT2i would not work in patients eGFR below 45?
- “Meet the Experts” – Live Q&A - 59:19 Putting cost aside, would you consider SGLT2i as first line therapy? - 1:00:55 Which would you start GLP1 RA vs SGLT2i? - 1:03:48 Where does it lead metformin in management of T2D? - 1:05:58 How concerned are we about hypoglycemia with SGLT2i? - 1:09:01 What is the risk of DKA? - 1:12:20 Is there any intercurrent events disturb patients i.e. stroke, AKI? - 1:14:13 Is there a threshold of GFR drop? - 1:16:21 Are there any other ways to look at kidney damage? - 1:19:45 If a patient is already on metformin and DPP4i, would you stop that or add SGLT2i? - 1:21:13 Are there patients where you have to reduce anti-hypertensive medication? Or elderly or frail patients? - 1:23:10 How do you manage GTI? How frequently you see it? - 1:25:57 Do you have any advices in Asian patients with GLR and body weight levels in the use of SGLT2i? - 1:26:48 Is it something to consider in patients with ketogenic diet, impermanent fasting or fasting period?
- 1:28:52 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 9:46 Organ protection at the heart of T2D management by Prof. Thomas
- Panel Discussion: Diabetes – Organ Protection is everyone’s responsibility 22:17 Patient case introduction
- Meet the Experts: Q&A session 43:29 SGLT2i class effect? 48:01 What does “Early” patient mean? High risk? 50:55 How to intervene early? Recommended eGFR or UACR? 56:18 GLP1 RA for high BMI, high ASCVD risk, high UACR?
- 1:01:29 SGLT2i: beyond the glucose lowering effects 1:24:03 Panel Discussion: Gift the gift that protects failing hearts 1:44:40 Meet the Experts: Q&A session 2:03:12 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 8:28 Panel Discussion: Unravelling the guidelines 09:04 EASD/ADA by Prof. Thomas 14:10 NICE by Prof. Jarvis 16:51 ESC by Prof. Zieroth 19:27 KDIGO by Prof. Groop 27:58 Patient case discussion 34:34 Piecing together the puzzle for patients by Prof. Jarvis 57:20 Meet the Experts Open forum: “What would you do with this patient?”Discussion on patient case submitted 1:20:50 Meet the Experts: Q&A session 1:38:21 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 5:22 Providing hope for diabetic kidney disease by Prof Rossings Panel Discussion: Don’t wait till it’s too late 35:31 Major points to highlight from the talk 37:36 Gap between evidence and practice, what are the main barriers? 45:14 Perceived safety of SGLT2i & how to use SGLT2i in which eGFR? 48:34 Monitoring of renal function when you start SGLT2 49:39 How should we be looking for HF early? Meet the Experts & Q&A session 54:16 Should we use different dose of Empagliflozin in T2D and in HF? 55:37 SGLT2i concerns around hypoglycemia? 58:55 Perception around SGLT2is’ metabolic effects 1:04:02 Newly diagnosed patients need to be on SGLT2i without managing A1c? 1:06:19 What is guidance of using SGLT2i in acute HF/Kidney disease setting? 1:14:47 Do SGLT2is improve albuminuria? Class effect? 1:17:10 Mechanism of action of SGLT1? 1:18:31 Should statin be included in T2D patients even if their cholesterol level is normal? 1:19:57 Do SGLT2is cause polyuria? Role of Cystatin c to better manage CKD? 1:21:58 Relative and absolute risk reduction of SGLT2i around prophylaxis for future heart failure events? 1:24:30 For patients with T2D whose glucose is controlled but with risk factors for kidney disease, should SGLT2i be added? 1:25:57 Take 5 summary
